| 摘要: |
| 目的：观察复方甘草酸苷片联合联合双歧杆菌三联活菌胶囊（培菲康）治疗儿童非酒精性脂肪性肝病（NAFLD）的临床疗效和安全性。方法：选择2015年12月到2018年2月我院诊治的NAFLD患儿136例，使用随机数字表法将患儿分为对照组和观察组各68例。对照组给予复方甘草酸苷片，观察组给予复方甘草酸苷片+双歧杆菌三联活菌胶囊（培菲康），疗程24周，比较两组临床疗效和不良反应发生情况。结果：治疗后观察组IL-6、TNF-α、AST、ALT、HA、LN、PC Ⅲ和C Ⅳ分别为（15.64±2.82）μg/L、（25.63±5.14）μg/L、（51.72±10.33）U/L、（57.48±10.65）U/L、（117.25±21.46）ng/mL、（55.62±10.24）ng/mL、（85.61±14.92）ng/mL和（70.35±12.72）ng/mL，均显著低于对照组的（22.23±3.68）μg/L、（36.82±6.38）μg/L、（64.35±11.24）U/L、（70.14±13.52）U/L、（162.43±31.35）ng/mL、（87.56±15.14）ng/mL、（120.26±21.57）ng/mL和（102.37±19.43）ng/mL（P<0.05）。对照组临床治疗有效率为76.5%，显著低于观察组的92.6%（P<0.05）。对照组不良反应发生率为7.4%，观察组不良反应发生率8.8%，两组不良反应发生率比较差异无统计学意义（P>0.05）。结论：复方甘草酸苷片联合双歧杆菌三联活菌胶囊（培菲康）抑制NAFLD患儿炎症反应和肝纤维化，临床疗效显著，使用安全。 |
| 关键词: 复方甘草酸苷片 双歧杆菌三联活菌胶囊 儿童 非酒精性脂肪性肝病 |
| DOI：doi:10.13407/j.cnki.jpp.1672.108X.2019.12.007 |
|
| 基金项目: |
|
| The Effect of Compound Glycyrrhizin Tablets Combined Bifidobacterium Triad Capsule on Non-Alcoholic Fatty Liver Disease In Children |
| Lin Lufei, Lu Weicheng |
| (The NO.3 People's Hospital of Haikou, Hainan Haikou 571300, China) |
| Abstract: |
| Objective: To detect the effect of compound glycyrrhizin tablets combined Bifidobacterium triad capsule (Bifico) on non-alcoholic fatty liver disease (NAFLD) in children. Methods: A total of 136 NAFLD were children enrolled in this study. Who were divided into: control group (n=68) and observation group (n=68). The control group was given compound glycyrrhizin tablets for 24 weeks. The observation was given compound glycyrrhizin tablets and Bifico for 24 weeks. The clinical efficacy and adverse reactions rate was compared. Results: After treatment, IL-6, TNF-α, AST, ALT, HA, LN, PC Ⅲ, and C Ⅳ expression were 15.64±2.82 μg/L, 25.63±5.14 μg/L, 51.72±10.33 U/L, 57.48±10.65 U/L, 117.25±21.46 ng/mL, 55.62±110.24 ng/mL, 85.61±14.92 ng/mL, and 70.35±12.72 ng/mL in observation group, which was significantly lower than that of 22.23±3.68 μg/L, 36.82±6.38 μg/L, 64.35±11.24 U/L, 70.14±13.52 U/L, 162.43±31.35 ng/mL, 87.56±15.14 ng/mL, 120.26±21.57 ng/mL, and 102.37±19.43 ng/mL in control group (P<0.05). The clinic effective rate in control was 76.5%, which was lower than that of 92.6% in observation group (P<0.05). The adverse reactions rate was 7.4% in control group and 8.8% in observation group, there was no significant difference between the two groups (P>0.05). Conclusion: Compound glycyrrhizin tablets combined with Bifico can inhibit inflammatory reaction and liver fibrosis in NAFLD children, with effectively clinical efficacy and safety. |
| Key words: compound glycyrrhizin tablets bifidobacterium triad capsule children non-alcoholic fatty liver disease |
